Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by G1 Therapeutics Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) May 28, 2024 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting May 23, 2024 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses May 22, 2024 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights May 01, 2024 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib May 01, 2024 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights February 28, 2024 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee February 12, 2024 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference January 08, 2024 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy December 05, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium November 29, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights November 01, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO) October 18, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) October 27, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium October 16, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights August 02, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) July 31, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy June 04, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer May 16, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC) May 10, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights May 03, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights March 01, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) February 13, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib January 09, 2023 From G1 Therapeutics Via GlobeNewswire Tickers GTHX Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment December 07, 2022 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Announces Closing of Offering of Common Stock November 22, 2022 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Announces Pricing of Offering of Common Stock November 17, 2022 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Announces Proposed Public Offering of Common Stock November 17, 2022 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights November 02, 2022 From G1 Therapeutics Via GlobeNewswire Tickers GTHX Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC) November 02, 2022 From G1 Therapeutics Via GlobeNewswire Tickers GTHX G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC) October 10, 2022 From G1 Therapeutics Via GlobeNewswire Tickers GTHX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.